NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01091831,"Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects",https://clinicaltrials.gov/study/NCT01091831,,COMPLETED,"This is a multicenter, randomized, open label study designed to compare the efficacy and safety of lenalidomide with low-dose alkylating agents versus high-dose melphalan followed by stem cell support in newly diagnosed symptomatic MM patients who are 65 years of age or younger.",NO,Multiple Myeloma,DRUG: Cyclophosphamide|DRUG: Lenalidomide|DRUG: Dexamethasone|DRUG: Melphalan,"Progression free survival, 5 years","Overall survival, 5 years",,Fondazione EMN Italy Onlus,,ALL,"ADULT, OLDER_ADULT",PHASE3,389,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,RV-MM-EMN-441,2009-07,2021-09,2024-07-01,2010-03-24,,2024-11-06,"Division of Hematology, A.O.U. Citt√† della Salute e della Scienza di Torino, Torino, 10126, Italy",
